Advertisement

Topics

AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade

02:08 EDT 20 Jun 2017 | RTTNews

Today's Daily Dose brings you news about Amgen's regulatory catalyst for next February; Axsome's new addition to its Board; Clovis' ARIEL3 results; Exelisis' CABOSUN study; Lipocine's study results of oral testosterone candidate LPCN 1021; FDA approval of Neos' ADHD medication and Seattle Genetics' CASCADE disappointment.

Original Article: AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade

NEXT ARTICLE

More From BioPortfolio on "AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...